Loading
Life sciences · Journal article
Transplantation · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
BACKGROUND: Type 2 diabetes mellitus (T2DM) is frequent after heart transplantation (HT) and is exacerbated by immunosuppressive therapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may improve metabolic control, but data in HT recipients are limited. METHODS: We performed a retrospective, multicenter study including HT recipients with T2DM from 14 Spanish centers. In patients treated with GLP-1 RAs, we assessed antidiabetic and immunosuppressive therapies, adverse events, and changes in metabolic parameters, insulin dose, and immunosuppressant trough levels during the first year after GLP-1 RA initiation. RESULTS: Among 734 HT recipients with T2DM (2011-2021), 108 (14.7%) received GLP-1 RAs (mean age 55.4 ± 9.0 y; 79.6% male), initiated 4.0 ± 3.1 y post-HT. At baseline, 64.8% had obesity. Semaglutide was used in 59%, dulaglutide in 27%, liraglutide in 13%, and tirzepatide in 1%; 41.7% achieved the maximum therapeutic dose. After 1 y, significant reductions were observed in body weight (-6.2 kg; 95% confidence interval [CI], -7.7 to -4.5 kg), fasting glucose (-27 mg/dL; 95% CI, -41 to -7 mg/dL), glycated hemoglobin (-0.74%; 95% CI, -1.12% to -0.35%), total cholesterol (-12 mg/dL; 95% CI, -19 to -6 mg/dL), low-density lipoprotein cholesterol (-8 mg/dL; 95% CI, -14 to -2 mg/dL), triglycerides (-29 mg/dL; 95% CI, -53 to -5 mg/dL), and systolic blood pressure (-3.6 mm Hg; 95% CI, -6.4 to -0.9 mm Hg). Tacrolimus trough levels decreased modestly (-0.7 ng/mL; 95% CI, -1.4 to -0.1 ng/mL; P = 0.025), without episodes of acute rejection. Gastrointestinal adverse events occurred in 12.0%, leading to discontinuation in 3.7%. CONCLUSIONS: In HT recipients with T2DM, GLP-1 RAs were associated with improved glycemic and cardiometabolic parameters and were generally well tolerated. These findings support the use of GLP-1 RAs as a valuable therapeutic strategy for the management of T2DM after HT.